Mifepristone Tablets 25mg 6 Tablets

• Application: Gynaecology
• Usage Mode: For oral administration
• Suitable for: Adult
• State: Solid
• Shape: Tablet
• Type: Organic Chemicals
• Model NO.: unapplicable
• Pharmaceutical Technology: Chemical Synthesis
• Drug Reg./Approval No.: H20093211
• H.S Code: 3004909090
• Product: Mifeprostone Tablet
• Function: Medicine Termination Pregnancy
• Transport Package: Box
• Specification: 25 mg
• Trademark: Ding Rou
• Origin: China
• HS Code: 3004909090
• Production Capacity: 100000 Boxes/Week

Product Description

Mifepristione Tablets

[component]
The main ingredient of this product is mifepristone.

[character]
This product is yellowish.

[indication]
This product is suitable for sequential combination of mifepristone tablets and prostaglandins, and can be used to terminate pregnancy within 49 days after menopause.

[Usage and dosage]
Healthy early pregnant women who have stopped menstruation ≤ 49 days, take orally 25-50mg mifepristone tablets twice a day for 2-3 days after fasting or taking food for 2 hours, with a total amount of 150mg, fast for 2 hours after taking the drug each time, and take orally misoprostol 600 in the morning of 3-4 days μ G Or one methyl carboprost suppository (lmg) was placed in the posterior vaginal vault. Rest in bed for 1-2 hours, and observe for 6 hours in the outpatient department. Pay attention to the bleeding after medication, and whether there are pregnancy products and side effects.

[Adverse reactions]
1. Individual women may develop skin rashes.
2. After using prostaglandins, there may be abdominal pain, vomiting and diarrhea in some subjects.
3. A few have flush and numbness.
4. Some early pregnant women have mild nausea, vomiting, dizziness, fatigue, lower abdominal pain, anal distension and uterine bleeding after taking the medicine.

[taboo]
1. People who are allergic to this product.
2. Patients with heart, liver and kidney diseases and adrenal cortex insufficiency.
3. Those who have contraindications to use prostaglandins: such as glaucoma, asthma, and allergy to prostaglandins.
4. Pregnancy with intrauterine device and suspected ectopic pregnancy, smoking women over 35 years old.
matters needing attention
1. For those confirmed as normal intrauterine pregnancy, the duration of menopause should not exceed 49 days, and the maximum duration should not exceed 56 days.
2. Mifepristone tablets must be used in clinical units with emergency, curettage, transfusion and blood transfusion conditions. Please use it under the guidance of a doctor.
3. Before taking the medicine, the user must be informed of the treatment effect and possible side effects.
4. After taking the medicine, a small amount of vaginal bleeding usually occurs earlier, and some women have a longer bleeding time after abortion. A few early pregnant women can have spontaneous abortion after taking mifepristone tablets. About 80% of pregnant women excrete villi or fetal sac within 6 hours after using prostaglandins, and about 10% of pregnant women excrete pregnancy products within one week after taking prostaglandins.
5. You should go to the original treatment unit for further consultation 8-15 days after taking the medicine to determine the effect of abortion. B ultrasonic examination or blood test shall be performed when necessary β The determination of human chorionic gonadotropin (HCG) should be handled in time if the diagnosis is incomplete abortion or continued pregnancy.
6. Those who fail to terminate early pregnancy with this product must undergo induced abortion.
7. Drugs for pregnant women and lactating women: except for terminating early pregnancy, other drugs are prohibited.
8. Drug use for children: there is still no research data on the safety and effectiveness of this product for children.
9. Medication for the elderly: There is still lack of research data on the safety and effectiveness of this product for elderly patients.
10. Drug overdose: According to literature reports, in the tolerance study, no serious adverse reactions were reported after a single oral dose of 1800mg mifepristone was given to healthy non pregnant women and men. If the patient ingests much more than the dose, close attention should be paid to signs of adrenal failure.

[Drug interaction]
Avoid taking aspirin and other NSAIDs within one week after taking this product.

[pharmacological action] 
Mifepristone is a receptor level antiprogesterone drug, which has the effects of terminating early pregnancy, anti implantation, inducing menstruation and promoting cervical maturity. It competes with progesterone to achieve the effect of antagonizing progesterone, and has certain binding power with glucocorticoid receptor. Mifepristone can significantly increase the sensitivity of pregnant uterus to prostaglandins. Small doses of mifepristone combined with prostaglandins in sequence can obtain satisfactory results in terminating early pregnancy.

[Pharmacokinetics]
The 25 mg oral mifepristone absorbed rapidly, with an average peak time of 0.9 ± 0.5 hours, and an average blood drug peak of 1.1 ± 0.41 mg/L, showing significant individual differences. The elimination half-life is 26 hours. Non pregnant women generally reach the peak faster, the blood concentration is higher, and the elimination half-life is longer. This product has obvious first pass effect. After 1-2 hours of oral administration, the level of metabolites in the blood can exceed that of the parent compound.

Storage method
Protect from light and seal.

[Validity]
60 months